Table 1.

ALK-positive NSCLC patients with acquired resistance to crizotinib. Adeno, adenocarcinoma; NA, tissue not available; BAC, bronchioloalveolar component.

Patient	Duration (months)*	Timing (months)†	Histology	ALK fusion	ALK-amplified	ALK mutation	Phospho-EGFR (pre-crizotinib)	Phospho-EGFR (post-crizotinib)	CKIT FISH
MGH0NZ	20	0	Adeno	Positive	No	No	1+	1+ (solid) 2+ (BAC)	Amplified (solid)
MGH001	4	3.5	Adeno	Positive	No	No	NA	1+	No
MGH010	8	0	Adeno	Positive	No	No	2+	1+	No
MGH011	34	0	Adeno	Positive	No	S1206Y	2+	2+	No
MGH013	9	0	Adeno	Positive	No	No	NA	2+	No
MGH016	6	6	Adeno	Positive	No	No	1+	2+	No
MGH017	23+	0	Adeno	Positive	No	No	0	2+	No
MGH018	10	0.5	Adeno	Positive	No	G1202R	2+	2+	Focal amplification
MGH019	8	<0.5	Adeno	Positive	No	No	NA	NA	NA
MGH020	13	0	Adeno	Positive	No	L1196M	NA	NA	NA
MGH021	12	3	Adeno	Positive	No	1151Tins	1+	2+	No
MGH022	6	0	Adeno	Positive	No	No	NA	2+	No
MGH023	12	0	Adeno	Positive	No	No	2+	1+	No
MGH024	15	0	Adeno	Positive	No	No	2+	2+	No
MGH025	11	0	Adeno	NA	NA	No	NA	2+	No
MGH027	4	1	Adeno	NA	NA	No	NA	NA	NA
MGH028	14	1	Adeno	NA	NA	No	1+‡	NA	NA
MGH029	8	0	Adeno	Positive	Yes	No	NA	0	NA

^*Approximate duration of crizotinib therapy. “+” indicates that the patient remains on crizotinib.

^†Approximate time between the last crizotinib dose and the repeat biopsy. “0” indicates that the patient was still taking crizotinib at the time of the biopsy.

^‡This sample had focal areas with 2+ staining.